You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ALCL

Showing 1 - 25 of 79
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pediatric Anaplastic Large Cell Lymphoma Trial in Shanghai (P regimen, Course A1 + Vin, Course B1 +Vin)

Recruiting
  • Pediatric Anaplastic Large Cell Lymphoma
  • P regimen
  • +7 more
  • Shanghai, China
    Shanghai Children's Medical Center
Jul 23, 2022

Anaplastic Large Cell Lymphoma, ALK-Positive, Inflammatory Myofibroblastic Tumor, Other Solid Tumor Trial in Utrecht

Recruiting
  • Anaplastic Large Cell Lymphoma, ALK-Positive
  • +2 more
  • Paris, France
  • +1 more
Sep 27, 2022

ALK+ Anaplastic Large Cell Lymphoma Trial in Wien (Brentuximab vedotin, Imatinib)

Terminated
  • ALK+ Anaplastic Large Cell Lymphoma
  • Wien, Austria
    Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abte
Feb 15, 2022

Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) Trial in Belgium, France (BIA-ALCL)

Recruiting
  • Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)
  • BIA-ALCL
  • Bruges, Belgium
  • +30 more
Jul 23, 2021

Leukemic Phase of ALCL

Recruiting
  • Anaplastic Lymphoma
    • Strasbourg, France
      Hematology Laboratory - Strasbourg University Hospitals
    Jul 7, 2021

    Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)

    Recruiting
    • Anaplastic Large Cell Lymphoma
    • Vinorelbine
    • Shanghai, Shanghai, China
      Shanghai Children's Medical Center
    Jul 28, 2021

    Lymphoma Trial in Worldwide (cyclophosphamide, cytarabine, dexamethasone)

    Completed
    • Lymphoma
    • Vienna, Austria
    • +9 more
    May 24, 2022

    Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL) Trial in Guangzhou (TQ-B3101 capsule)

    Unknown status
    • Relapsed/Refractory Anaplastic Large Cell Lymphoma (ALCL)
    • TQ-B3101 capsule
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Mar 11, 2020

    Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

    Active, not recruiting
    • ALK-Positive Anaplastic Large Cell Lymphoma
    • RNAseq
    • Toulouse, France
      IUCT-Oncopole University Hospital
    Jul 3, 2023

    Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)

    Completed
    • Anaplastic Large Cell Lymphoma
    • Vinorelbine
    • Shanghai, Shanghai, China
      Shanghai Children's Medical Center
    Jul 23, 2022

    Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma Trial in New York, Vancouver, Toronto (Brentuximab Vedotin, Bendamustine,

    Completed
    • Hodgkin Lymphoma
    • Anaplastic Large Cell Lymphoma
    • Brentuximab Vedotin
    • +2 more
    • New York, New York
    • +2 more
    Jul 15, 2020

    Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

    Active, not recruiting
    • Peripheral T Cell Lymphoma
    • Pediatric Hodgkin Lymphoma
    • Brentuximab Vedotin (Genetical Recombination)
    • Tokyo, Japan
      Takeda Selected Site
    Oct 11, 2022

    Lymphoma Trial in Houston (Brentuximab Vedotin)

    Terminated
    Has Results
    • Lymphoma
    • Brentuximab Vedotin
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Nov 15, 2019

    Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

    Completed
    Has Results
    • Peripheral T Cell Lymphoma
    • +18 more
    • Vancouver, British Columbia, Canada
    • +29 more
    Apr 29, 2022

    Peripheral T-Cell Lymphoma (PTCL NOS), Nodal Lymphomas of T Follicular Helper (TFH), Follicular T-cell Lymphoma (FTCL) Trial

    Withdrawn
    • Peripheral T-Cell Lymphoma (PTCL NOS)
    • +8 more
    • (no location specified)
    Mar 10, 2020

    Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and

    Recruiting
    • Breast Implant-Associated Anaplastic Large Cell Lymphoma
    • +2 more
      • London, United Kingdom
      • +1 more
      Aug 17, 2021

      Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)

      Recruiting
      • Newly Diagnosed Peripheral T-cell Lymphoma
      • Nanjing, Jiangsu, China
        Hematological Department, People's Hospital of Jiangsu Province
      Jun 1, 2023

      Anaplastic Large Cell Lymphoma, ALK-Positive Trial in Philadelphia (Brigatinib)

      Withdrawn
      • Anaplastic Large Cell Lymphoma, ALK-Positive
      • Philadelphia, Pennsylvania
        Fox Chase Cancer Center
      Jan 4, 2021

      Hematologic Cancers, Solid Tumors, Metastatic Cancer Trial in Villejuif (Crizotinib)

      Active, not recruiting
      • Hematologic Cancers
      • +2 more
      • Villejuif, Ile De France, France
        Gustave Roussy
      Sep 5, 2022

      Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

      Active, not recruiting
      • Anaplastic Large Cell Lymphoma
      • +4 more
      • Duarte, California
      • +3 more
      Jul 21, 2022

      Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))

      Recruiting
      • Locally Advanced Solid Tumors
      • +3 more
      • Oral repotrectinib (TPX-0005)
      • Los Angeles, California
      • +27 more
      Aug 9, 2022

      Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

      Not yet recruiting
      • Adult T-cell Leukemia/Lymphoma
      • +4 more
      • CC-486 (5-azacitidine)
      • +3 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Aug 17, 2022

      Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral Trial (SGN-35T)

      Not yet recruiting
      • Lymphoma, T-Cell, Cutaneous
      • +5 more
      • (no location specified)
      Nov 2, 2023

      T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

      Not yet recruiting
      • T-Cell Lymphoma
      • (no location specified)
      Jul 22, 2022

      Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies Trial in Worldwide (Durvalumab / Tremelimumab Combination

      Active, not recruiting
      • Pediatric Cancer
      • +2 more
      • Durvalumab / Tremelimumab Combination Therapy
      • Baltimore, Maryland
      • +18 more
      Nov 3, 2022